Related Experiment Videos
Molecular therapy for glioblastoma
G Karpati1, H Li, J Nalbantoglu
1Montreal Neurological Institute, 3801 University Street, Montreal, Quebec H3A 2B4, Canada. mcgk@musica.mcgill.ca
Abstract:
Glioblastoma (GB), the relatively frequent and most malignant form of primary brain tumor, is fatal within 1 to 2 years of onset of symptoms, despite conventional therapy. Molecular therapy promises to be an effective and possibly curative treatment. Several molecular strategies have been tested, either in animal models or clinical trials. These include: prodrug activating systems, introduction of tumor suppressor or cell-cycle-related genes, inhibition of growth factors and/or their receptors, inhibition of neovascularization, immunomodulatory maneuvers, oncolytic viruses and inhibition of matrix metalloproteinases. Of special interest for the development of optimal molecular therapy of GB, is the choice of the most efficient and least toxic gene vectors (adenovirus, retrovirus, herpes simplex virus), the route of administration of the therapeutic agent (intratumoral with or without debulking and intracarotid), avoidance of collateral damage to the perineoplastic neuropil and adequate preclinical studies. The ultimate molecular therapy will probably involve the application of multiple simultaneous (combinatorial) therapeutic modalities. The safety and efficiency of these in humans can only be judged by properly controlled therapeutic trials.
Insights
Molecular therapy offers hope for glioblastoma (GB), a deadly brain cancer. Research explores various strategies like gene therapy and oncolytic viruses to improve patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Therapy
Background:
- Glioblastoma (GB) is the most common and malignant primary brain tumor, with a poor prognosis of 1-2 years despite conventional treatments.
- Molecular therapies represent a promising avenue for effective and potentially curative treatment of glioblastoma.
Purpose of the Study:
- To review and discuss various molecular strategies for glioblastoma treatment.
- To highlight key considerations for developing optimal molecular therapies, including gene vectors, administration routes, and preclinical studies.
Main Methods:
- Review of existing molecular strategies tested in animal models and clinical trials.
- Discussion of gene vectors (adenovirus, retrovirus, herpes simplex virus) and administration routes (intratumoral, intracarotid).
- Emphasis on minimizing collateral damage and the importance of preclinical validation.
Main Results:
- Several molecular strategies show potential, including prodrug systems, gene therapy, growth factor inhibition, anti-angiogenesis, immunotherapy, oncolytic viruses, and MMP inhibitors.
- Optimal molecular therapy requires careful selection of gene vectors and administration routes to maximize efficacy and minimize toxicity.
- Combinatorial approaches involving multiple simultaneous therapeutic modalities are likely the future of glioblastoma treatment.
Conclusions:
- Molecular therapy holds significant promise for treating glioblastoma.
- Careful consideration of gene vectors, delivery methods, and minimizing off-target effects are crucial for successful clinical translation.
- Rigorous, controlled therapeutic trials are essential to evaluate the safety and efficacy of these advanced glioblastoma treatments.